“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
Patients with chronic spontaneous urticaria (CSU) experienced improved quality of life and sleep when symptoms were mitigated ...
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...
Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...
In the KEYNOTE-B96 trial ( NCT05116189 ), weekly paclitaxel with bevacizumab and pembrolizumab (Keytruda; Merck) demonstrated ...
Eleanor Perfetto, PhD, explores how most favored nation policy relates to broader drug pricing and cost-effectiveness debates ...
Among adults surveyed, 27.8% (95% CI, 25.7-29.8) received all telemental health care, 21.5% (95% CI, 19.8-23.1) received ...
While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...
Patients with rheumatoid arthritis (RA) have a higher risk of osteoporotic fractures if they have elevated adipokines, according to a recent report. 1 However, the investigators behind the study, ...
Zachary Contreras from Sharp Health Plan discusses findings from the AMCP Nexus study showing that dextromethorphan-bupropion ...
Zachary Contreras from Sharp Health Plan explains how managed care organizations can support early adoption of DM-BUP to ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback